Core 2: Drug Development

  • The goal is to accelerate drug development by identifying existing molecules/drugs that can be applied specifically to GBM, both on their own and in rational combination, as well as develop novel drugs (at MD Anderson) specifically for GBM.
  • The work of this core will also include research to better understand the molecular and biological response to clinical inhibitors at the “systems biology” level to develop rational combination therapies.
  • Simultaneous investigation in the other research cores will aid the team in creating and matching drugs with the right patients depending on the molecular profile of the patient’s tumor.